Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2014. The report details a share repurchase transaction executed on May 20, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 617,500 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,626.50 pence per share; lowest price paid was 1,616.50 pence per share.
- Treasury Holdings (Settled): 491,500,212 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 493,013,312 shares (10.15% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,859,022,496 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the repurchase of 617,500 shares. Consequently, the percentage of shares held in Treasury increased to 10.15% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares held in Treasury against the company's latest annual report.
- Confirm the calculation of total voting rights (4,859,022,496 shares) for disclosure threshold purposes.
- Review the settlement status of the 1,513,100 shares included in the "including unsettled" figure to determine final Treasury ownership.